Introduction
For several years now, the drumbeat in competition law circles has been concern over a perceived lack of enforcement in the face of increasing market concentration. Until recently, the main result appeared to be a marked increase in intervention against US tech giants including Google and Facebook. However, recent developments in both EU and UK merger control suggest that entities in other innovation-heavy sectors – including biotech and pharma – are likely to find themselves increasingly in the cross hairs, sometimes even where their links to the jurisdictions appear slight.[1]
At the EU level, the DNA sequencing giant, Illumina, finds itself locked in battle with the European Commission (EC) over its $7.1 billion…
